Eptacog alfa

DRUG2 trials

Sponsors

Novo Nordisk A/S, Leiden University Medical Center

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With InhibitorsPost Partum Hemorrhage

Phase 2

A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors

CompletedNCT03196284

Novo Nordisk A/SCongenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Start: 2017-08-10End: 2020-01-31Updated: 2021-10-22

Unknown Phase

NovoSeven® in Severe Postpartum Haemorrhage - Experiences From UK, DK, FR, NL

CompletedNCT04723979

Leiden University Medical CenterPost Partum Hemorrhage

Start: 2020-05-01End: 2021-01-31Updated: 2022-05-11

Related Papers

Concizumab prophylaxis in people with hemophilia A or B without inhibitors: patient-reported outcome results from the phase 3 explorer8 study.

2025-02-20

Concizumab prophylaxis in persons with hemophilia A or B with inhibitors: patient-reported outcome results from the phase 3 explorer7 study.

2024-05-019 citations

Efficacy and Safety Analyses of Recombinant Factor VIIa in Severe Post-Partum Hemorrhage

Journal of Clinical Medicine2024-05-013 citations

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Blood Advances2022-03-1542 citations

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Blood2021-11-056 citations

Improvement in Health-Related Quality of Life Measures after Long-Term, Daily, Subcutaneous Concizumab Prophylaxis in Patients with Hemophilia A/B with and without Inhibitors: Results from the Main and Extension Parts of Phase 2 Clinical Trials

Blood2021-11-052 citations

Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial

Blood2020-11-042 citations

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Blood2019-11-135 citations

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Blood2019-11-133 citations

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Blood2019-11-131 citations

Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.

2019-11-0198 citations